Fennec Pharmaceuticals Inc. is proposing a public offering of its common shares with underwriters.
The offering includes a 30-day option for additional share purchase.
Proceeds will be used for repurchasing certain indebtedness and general corporate purposes.
Proposed Offering of Common Shares
Fennec Pharmaceuticals plans to offer its common shares in an underwritten public offering.
Intended Use of Proceeds
The company intends to repurchase debt and allocate remaining funds for working capital and general purposes.
Underwriters for the Offering
Piper Sandler & Co. and Craig-Hallum Capital Group LLC are the joint book-running managers for the public offering.
Regulatory Compliance
The common shares will be offered following a registration statement declared effective by the SEC.
Offering Restrictions
The shares will not be offered or sold in Canada or to Canadian residents.
- Fennec Pharmaceuticals focuses on combating ototoxicity in cancer patients receiving cisplatin-based chemotherapy.
- The company's product, PEDMARK, aims to reduce the risk of platinum-induced ototoxicity in cancer patients.
The proposed offering of common shares by Fennec Pharmaceuticals aligns with its strategic plans for repurchasing debts and bolstering working capital. This move provides insights into the company's financial direction and growth aspirations.